Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Transfusion dependent thalassemia patients refractory to Hydroxyurea~Exclusion Criteria:~* Those with active systemic comorbidity, with past personal or family history of thrombophilia, recent fracture or recent major surgery

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thalidomide in combination with hydroxyurea (Type: EXPERIMENTAL): All the study patients refractory to hydroxyurea will be given thalidomide at an average dose of 2mg/kg/day (range 1-4mg/kg/day). Participants will also be continued on hydroxyurea at a dose of 10-20 mg/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).